Repligen (NASDAQ:RGEN) Price Target Raised to $200.00 at JPMorgan Chase & Co.

Repligen (NASDAQ:RGEN) had its price objective raised by analysts at JPMorgan Chase & Co. from $190.00 to $200.00 in a report issued on Friday,Benzinga reports. The brokerage presently has an “overweight” rating on the biotechnology company’s stock. JPMorgan Chase & Co.‘s price objective suggests a potential upside of 24.14% from the company’s previous close.

A number of other research firms have also weighed in on RGEN. TD Cowen began coverage on shares of Repligen in a research note on Monday, February 10th. They issued a “buy” rating and a $200.00 target price on the stock. Canaccord Genuity Group boosted their price objective on Repligen from $165.00 to $170.00 and gave the stock a “hold” rating in a research note on Friday. StockNews.com upgraded Repligen from a “sell” rating to a “hold” rating in a report on Friday, January 3rd. Canaccord Genuity Group initiated coverage on Repligen in a report on Tuesday, December 17th. They set a “hold” rating and a $165.00 price target on the stock. Finally, Wolfe Research started coverage on shares of Repligen in a report on Thursday, November 14th. They issued a “peer perform” rating for the company. Six research analysts have rated the stock with a hold rating and nine have issued a buy rating to the stock. Based on data from MarketBeat, Repligen has an average rating of “Moderate Buy” and a consensus price target of $183.36.

Repligen Price Performance

NASDAQ:RGEN traded down $1.56 during trading hours on Friday, reaching $161.11. 51,787 shares of the company were exchanged, compared to its average volume of 586,809. The company has a current ratio of 10.44, a quick ratio of 8.76 and a debt-to-equity ratio of 0.26. The firm has a market cap of $9.03 billion, a PE ratio of -435.42, a price-to-earnings-growth ratio of 4.23 and a beta of 0.99. Repligen has a twelve month low of $113.50 and a twelve month high of $203.13. The stock’s 50-day moving average is $155.17 and its 200-day moving average is $148.81.

Repligen (NASDAQ:RGEN) last released its earnings results on Thursday, February 20th. The biotechnology company reported $0.44 earnings per share for the quarter, beating the consensus estimate of $0.41 by $0.03. The business had revenue of $167.55 million for the quarter, compared to the consensus estimate of $167.58 million. Repligen had a positive return on equity of 3.90% and a negative net margin of 3.36%. On average, sell-side analysts anticipate that Repligen will post 1.54 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently modified their holdings of RGEN. GTS Securities LLC purchased a new stake in shares of Repligen in the fourth quarter valued at approximately $264,000. Gordian Capital Singapore Pte Ltd acquired a new stake in Repligen in the fourth quarter valued at $259,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its position in shares of Repligen by 12.8% during the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 235,343 shares of the biotechnology company’s stock worth $33,875,000 after purchasing an additional 26,733 shares in the last quarter. Two Sigma Advisers LP grew its position in Repligen by 6.7% during the fourth quarter. Two Sigma Advisers LP now owns 134,800 shares of the biotechnology company’s stock worth $19,403,000 after buying an additional 8,500 shares during the period. Finally, Raiffeisen Bank International AG acquired a new position in Repligen during the fourth quarter worth about $29,000. 97.64% of the stock is currently owned by hedge funds and other institutional investors.

Repligen Company Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.